Clinical, pathological features and prognosis of renal carcinoma: A single-center analysis of 4167 cases / 解放军医学杂志

ABSTRACT

Objective: To analyze the clinical characteristics, pathological features and prognosis of 4167 patients with renal carcinoma. Methods: The clinical data of 4167 patients with renal carcinoma were retrospectively studied who were admitted and received renal cancer surgery in the First Medical Center of Chinese PLA General Hospital from Jan. 2008 to Sep. 2016. All the cases were followed up for 40(2-99) months. The general data, pathological features, tumor-node-metastasis (TNM) stage, tumor diameter, surgical and postoperative clinical indicators, postoperative metastasis of renal carcinoma, and postoperative mortality and survival of patients were analyzed. Results: The male-female ratio of the 4167 cases was 72.2%(3010 cases) and 27.8%(1157 cases) (2.6:1), age of ill onset was 0.3-86(52.4 ± 12.4) years old, high incidence age was 45-65 years old. Case load diagnosed with and without symptom was 20.7% (863 cases) and 79.3% (3304 cases), respectively. In pathological diagnosis, 3670 cases of suprarenal epithelioma accounted for 88.1% in all cases. Minimally invasive surgery was 3821 cases (91.7%), nephron sparing surgery (NSS) was 1698 cases (40.7%), radical nephrectomy (RN) was 2466 cases (59.2%), open surgery was 346 cases (8.3%), transperitoneal approach rate was 16.9% (705 cases) and retroperitoneal approach rate was 83.1% (3462 cases). The overall survival rate at 1, 3 and 5 year post-operation was 98.1%, 94.8% and 92.0%, respectively. Cancer specific survival rate (1, 3, 5 year) was 98.6%, 96.2% and 94.6%, respectively. Tumor-free survival rate was 96.4%, 92.8% and 90.7%, respectively. Conclusions: The high incidence age of renal cancer is about 50 years old, the prevalence rate of men is 2.6 times higher than that of women. The main pathological type of renal cancer is suprarenal epithelioma. The rate of asymptomatic consultation rate has increased significantly. Minimally invasive surgery is the main treatment method for kidney cancer. The 5-year overall survival rate of renal cell carcinoma has exceeded 91%, and the long-term prognosis is better.